HAART

ApprovedSmall molecule

Bayer

HAART is one of 92 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

AsthmaActive, not recruiting

GrowthActive, not recruiting

HIV InfectionPhase 1/Phase 2

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

HAART

Bayer

Approved

1 2

Singulair

AstraZeneca

Preclinical

17 3

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 4

Atrovent

Boehringer Ingelheim

Preclinical

5 5

Formoterol Fumarate

AstraZeneca

Preclinical

8 6

Symbicort

AstraZeneca

Preclinical

6 7

Aciphex

Akero Therapeutics

Preclinical

2 8

Atrovent

Boehringer Ingelheim

Preclinical

2 9

Tylenol

KKenvue Brands

Preclinical

1 10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2033

Phase 3Recruiting

HIV Infection

NCT00796263

Clinical

Trials by Indication[1]

HIV infection3 trials

Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).

Completed·JJuan A. Arnaiz·Phase 4·NCT00979706·22 enrolled

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Completed· Bayer logo

Bayer·Phase 1/2·NCT00059462·56 enrolled

Antiretroviral Therapy for Acute and Chronic HIV Infection

Recruiting·SSEARCH Research Foundation·Phase 3·NCT00796263·900 enrolled

Antiretroviral Treatment2 trials

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00071890·148 enrolled

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Completed· GSK logo

GSK·Phase 2·NCT00945282·8 enrolled

Asthma1 trial

Children With HIV and Asthma (CHIVAS)

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·N/A·NCT01644370·20 enrolled

Immunization1 trial

Single DermaVir Immunization in HIV-1 Infected Patients on HAART

Completed·GGenetic Immunity·Phase 1·NCT00712530·9 enrolled

Interleukin1 trial

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

Completed·UUniversity of Pennsylvania·Phase 1·NCT01013415·17 enrolled

11 more indications

Chronic1 trial

Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00339456·155 enrolled

Monotherapy1 trial

HIV - Monotherapy in Switzerland (MOST-ch)

Terminated·—·Phase 4·NCT00531986·60 enrolled

Gene Therapy1 trial

Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

Unknown status·GGenexine, Inc.·Phase 1·NCT00517569·12 enrolled

Pediatric HIV1 trial

Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

Terminated·UUniversity of Washington·N/A·NCT00428116·140 enrolled

Drug Monitoring1 trial

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00032669·34 enrolled

HIV1 trial

Valproic Acid and Its Effects on HIV Latent Reservoirs

Completed·JJean-Pierre Routy·Phase 2·NCT00289952·50 enrolled

T Cell1 trial

Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)

Completed·GGenetic Immunity··NCT00918840·16 enrolled

Immune Response1 trial

ARVs to Prevent Breastmilk HIV:Viral and Immune Responses

Completed·UUniversity of Washington·Phase 2·NCT00167674·58 enrolled

Growth1 trial

Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00287677·33 enrolled

Medication1 trial

Intermittent Versus Continuous Medication in the Treatment of HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00001967·123 enrolled

Effectiveness1 trial

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001131·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for HAART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HAART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HAART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

HAART

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2033

Trials by Indication[1]

HIV infection3 trials

Antiretroviral Treatment2 trials

Asthma1 trial

Immunization1 trial

Interleukin1 trial

Chronic1 trial

Monotherapy1 trial

Gene Therapy1 trial

Pediatric HIV1 trial

Drug Monitoring1 trial

HIV1 trial

T Cell1 trial

Immune Response1 trial

Growth1 trial

Medication1 trial

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News